Genmab — November 2018
-
Bluebird forsætter op. Gad vist om det er bb21217 eller LentiGlobin? https://seekingalpha.com/filing/4219307?app=1
-
Man er klar over hvilke problemer, der er med CAR-t og arbejder naturligt nok med forbedringer https://ash.confex.com/ash/2018/webprogram/Paper119247.html
-
Men havde analytikerne
ment at CAR-t ville snuppe en stor del af markedet, så ville de vel have skåret i topsalgsestimatet for Dara? -
Enig Solsen, men jeg undrer mig lidt over at de (på trods af CAR-t begejstringen), ikke decideret skærer ned på Dara topsalgsestimatet. Det giver ikke mening.
-
Ofatumumab was active and safe in these elderly chemoimmunotherapy-treated patients with SMZL. IRRs were generally mild and easily manageable, even in a cohort of patients with a very high median age and a relevant comorbidity burden. The ORR and the CR rate compare favorably with data reported in the literature with rituximab monotherapy also considering that >75% of patients have been previously exposed to rituximab.
-
this is what the genmab website says, http://www.genmab.com/product-pipeline/products-in-development/adct-301
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind